|
|
|
Xtalks, Online
2024-10-30
In the rapidly evolving field of gene editing, CRISPR technology has emerged as a revolutionary tool, enabling precise and efficient modifications to the genome. While the CRISPR-Cas9 system has garnered widespread attention for its ability to create double-strand breaks at specific DNA sites, the development of newer CRISPR-based tools, such as base editors (BEs) and prime editors (PEs), has significantly expanded the scope of genetic engineering.
Read more...
The expert speaker will provide a comprehensive overview of the current state of research in these areas, highlighting recent breakthroughs and discussing the potential of these technologies to transform genetic research and medicine. Attendees will gain insights into the latest advancements in the field, including the development of more efficient and versatile editors, improvements in delivery methods and efforts to reduce off-target effects.
Moreover, the webinar will explore the future applications of BE and PE, with a focus on their potential to address unmet medical needs. From correcting genetic mutations responsible for hereditary diseases to developing more effective cancer therapies, the possibilities are vast. The discussion will also touch on the ethical considerations and challenges associated with the clinical translation of these technologies, as well as the regulatory landscape that will shape their future use.
Join this webinar to explore the future of CRISPR and gene editing and discover how base and prime editing are poised to revolutionize the field of genetics.
Keywords: Genetic Engineering, Gene Therapy, CRISPR, Gene Editing, Biotechnology, Biotech, Genomics, Translational Research, Cell and Gene Therapy, Cell & Gene Therapies, Basic Research
|
|
|
|
|
|
|
Organized by:
|
|
Xtalks |
|
Invited Speakers:
|
|
Dr. Jiabao Lv, PhD, Senior Protein Scientist, GenScript
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2024-10-30
|
|
|
|
|
|
|
Registration:
|
|
Free Registration
|
|
E-mail:
|
|
tristan@xtalks.com
|
|
|
|
|
|
|
|
|
|
|
|